Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Pfizer, inc. save search
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Published: 2024-02-14 (Crawled : 14:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: 0.37%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -1.09%
H: 5.61%
C: 4.49%
first breast cancer trial therapeutics advanced
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.34%
H: 3.99%
C: 3.15%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 0.91%
H: 5.05%
C: 4.9%
arv-471 fda breast cancer treatment designation
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.78%
H: 0.3%
C: -0.84%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.4%
H: 0.07%
C: -0.92%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.21%
H: 0.72%
C: -0.11%
authorization cancer treatment application
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.56%
H: 1.25%
C: -0.33%
keytruda drug japan bladder cancer treatment application advanced
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -6.38%
H: 0.88%
C: 0.88%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.09%
H: 0.17%
C: -0.3%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.58%
H: 1.01%
C: -0.58%
keytruda bladder cancer treatment application advanced
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -3.69%
H: 1.71%
C: -2.41%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.1%
H: 0.46%
C: -0.06%
tivdak drug license review food cancer application
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.37%
H: 1.09%
C: 0.75%
talzenna cancer
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.17 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
padcev fda first approved bladder cancer treat advanced plus
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Published: 2023-12-06 (Crawled : 04:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: -1.03%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 5.35%
H: 26.96%
C: 24.13%
arv-471 conference breast symposium cancer program
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 22:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.27%
H: 1.51%
C: 1.04%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 1.72%
H: 4.07%
C: 0.6%
arv-471 breast symposium cancer
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Published: 2023-10-20 (Crawled : 10:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.42%
H: 0.16%
C: -1.32%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.6%
H: 0.61%
C: -0.56%
kisqali breast cancer risk novartis
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2023-10-12 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -0.57%
braftovi fda lung cancer cell
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.03%
H: 1.04%
C: -0.37%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.18%
H: 1.2%
C: -0.38%
xtandi cancer treatment
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.59%
H: 0.46%
C: 0.46%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.68%
H: 0.11%
C: -1.16%
xtandi fda review cancer grants
TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology
Published: 2023-08-17 (Crawled : 17:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.34%
H: 3.15%
C: 2.56%
cancer therapeutics platform
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Published: 2023-07-31 (Crawled : 21:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -0.73%
H: 2.32%
C: 1.3%
protac breast innovation cancer group designation
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.95%
H: 0.19%
C: -0.32%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.32%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.03%
H: 0.12%
C: -0.24%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: 0.13%
report business cancer treat global
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.4%
H: 0.3%
C: 0.01%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.56%
H: 1.05%
C: -1.16%
asco cancer pipeline meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.